Literature DB >> 19553932

New antithrombotic drugs.

P L Gross1, J I Weitz.   

Abstract

Thrombosis, both venous and arterial, is a major cause of morbidity and mortality worldwide. Consequently, there is an ongoing search for new antithrombotic drugs, particularly novel antiplatelet agents and anticoagulants. A better understanding of the biochemical pathways involved in platelet activation and coagulation and of the links between these systems and the impact of thrombosis on inflammation has led to the identification of new targets for antithrombotic drugs. This paper focuses on these new targets and new antiplatelet drugs and anticoagulants and describes the major advances in the continuing search for more potent antithrombotic drugs that have limited effects on hemostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553932     DOI: 10.1038/clpt.2009.98

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

Review 1.  Anticoagulation and psychotropic medications.

Authors:  Maurice Bachawati
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

Review 2.  Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays.

Authors:  Raj S Kasthuri; Sam L Glover; Jeremiah Boles; Nigel Mackman
Journal:  Semin Thromb Hemost       Date:  2010-10-26       Impact factor: 4.180

Review 3.  Cardiovascular drug therapy in the elderly: benefits and challenges.

Authors:  Jerome L Fleg; Wilbert S Aronow; William H Frishman
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

4.  Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist.

Authors:  M Dumas; F Nadal-Wollbold; P Gaussem; M Perez; T Mirault; R Létienne; T Bourbon; F Grelac; B Le Grand; C Bachelot-Loza
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  Update on heparin: what do we need to know?

Authors:  Daniel S Weitz; Jeffrey I Weitz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

6.  Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

Authors:  Ivan Stevic; Howard H W Chan; Leslie R Berry; Ankush Chander; Anthony K C Chan
Journal:  J Biochem       Date:  2012-10-24       Impact factor: 3.387

7.  Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.

Authors:  J Myerson; L He; G Lanza; D Tollefsen; S Wickline
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

Review 8.  Use of direct oral anticoagulants in daily practice.

Authors:  Feras Almarshad; Ali Alaklabi; Ebtisam Bakhsh; Aslam Pathan; Mosaad Almegren
Journal:  Am J Blood Res       Date:  2018-12-10

Review 9.  Reversal of novel oral anticoagulants in patients with major bleeding.

Authors:  Deborah M Siegal; Adam Cuker
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

10.  P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.

Authors:  Eduardo Ramacciotti; Daniel D Myers; Shirley K Wrobleski; K Barry Deatrick; Frank J Londy; John E Rectenwald; Peter K Henke; Robert G Schaub; Thomas W Wakefield
Journal:  Thromb Res       Date:  2009-12-04       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.